Abstract: Significantly high frequencies of 6 S-substitutions and one novel
RT-substitution,
rtH124N with 6.5-fold-reduced susceptibility to TDF in vitro, were noted at baseline in TDF non-responders than responders.
Method: The
rtH124N mutation identified in this study was introduced in WT-HBV clone (pJET-HBV-wt) by Site-Directed Mutagenesis (Agilent Technologies) with specific mutagenic oligonucleotides (rtH124N_F and rt
H124N_R) (Supplementary Table S6) to generate pJET-HBV-mt (
rt124N) that was confirmed by sequencing.
HBV mutation literature information.
PMID: 
2017
Scientific reports
